Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Username or Email Address

Password

Remember Me

Lost Password?

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

Amazon earnings primer: Why AI and tariffs are key to the second quarter

We’re lowering our price target on Bristol Myers as two key overhangs persist

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

Roblox stock soars 16% after revenue beat, strong user growth

Microsoft ends tradition of naming competitors in regulatory filings

OutPerformDaily

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

Tech Stocks
Cannabis Stocks
Index Funds
International
Short
Stock Picks

FTSE 100 LIVE: London markets lower as UK business confidence dips to two-year low

January 6, 2025

Tax rises and falling sales are worrying UK businesses, according to new data.

You may also like

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

July 31, 2025

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

July 31, 2025

Moloco SDK Is Now Available via Google AdMob and Ad Manager

Moloco SDK Is Now Available via Google AdMob and Ad Manager

July 31, 2025

Indices by TradingView

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors

July 31, 2025

Amazon earnings primer: Why AI and tariffs are key to the second quarter

July 31, 2025

We’re lowering our price target on Bristol Myers as two key overhangs persist

July 31, 2025

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

Stock Market Today: Indexes Trim Gains As Core Inflation Exceeds Views; Meta, Carvana Hit New Entries (Live)

July 31, 2025

Roblox stock soars 16% after revenue beat, strong user growth

July 31, 2025

Categories

3rdPartyFeeds
Cannabis Stocks
Index Funds
International
News
Short
Stock Picks
Tech Stocks
Uncategorized

Indices by TradingView

While subscribers receive the benefit of Outperformdaily opinions, none of the information contained therein constitutes a recommendation from Outperformdaily that any particular security, portfolio of securities, transaction, option, or investment strategy is suitable for any specific person. You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent any of the information contained in Outperformdaily may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Outperformdaily’s past results are not necessarily indicative of future performance. All investments are subject to loss. Our employees and writters typically personally invest in all recommendations, but they are not obligated too. Our employees and writters are prohibited from taking an opposite position from which they write about.